Review of ceftaroline fosamil microbiology: Integrated FOCUS studies

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue SUPPL.3, 2011, Pages

  Critchley, Ian A ^a   Eckburg, Paul B ^a   Jandourek, Alena ^a   Biek, Donald ^a   Friedland, H David ^a   Thye, Dirk A ^a  

^a Cerexa Inc   (United States)

Author keywords

Community acquired pneumonia; Penicillin binding proteins; Resistant pathogens; Streptococcus pneumoniae

Indexed keywords

AZITHROMYCIN; BETA LACTAM; CEFTAROLINE FOSAMIL; CEFTAZIDIME; CEFTRIAXONE; CLARITHROMYCIN; COTRIMOXAZOLE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; BINDING AFFINITY; BLOOD CULTURE; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; GRAM POSITIVE COCCI; HAEMOPHILUS INFLUENZAE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PENICILLIN RESISTANCE; REVIEW; SEROLOGY; STREPTOCOCCUS PNEUMONIAE; TREATMENT RESPONSE; URINALYSIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CEFTRIAXONE; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 79954622204     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr098     Document Type: Review

References (29)

1. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010; 122: 130-41.
2. Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents 2010; 36: 197-204.
3. Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of ceftaroline tested against contemporary (2008) bacteria isolated from community-acquired respiratory tract infections, including oxacillin- (methicillin) resistant Staphylococcus aureus. In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Poster #C2-1974. American Society for Microbiology, Washington, DC, USA.
4. Moore MR, Gertz RE Jr, Woodbury RL et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008; 197: 1016-27.
5. Bartlett JG, Dowell SF, Mandell LA et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-82.
6. Kollef MH, Shorr A, Tabak YP et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128: 3854-62.
7. Hageman JC, Uyeki TM, Francis JS et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12: 894-9.
8. Nakou A, Woodhead M, Torres A. MRSA as a cause of community-acquired pneumonia. Eur Respir J 2009; 34: 1013-4.
9. Ko WC, Paterson DL, Sagnimeni AJ et al. Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis 2002; 8: 160-6.
10. Marrie TJ, Fine MJ, Obrosky DS et al. Community-acquired pneumonia due to Escherichia coli. Clin Microbiol Infect 1998; 4: 717-23.
11. File TM Jr, Low DE, Eckburg PB et al. on behalf of the FOCUS 1 investigators. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 Suppl 3: iii19-32.
12. Low DE, File TM Jr, Eckburg PB et al. on behalf of the FOCUS 2 investigators. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 Suppl 3: iii33-44.
13. Eckburg P, Friedland HD, Lee J et al. FOCUS 1 and 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-acquired pneumonia (CAP). In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Poster #L1-345a. American Society for Microbiology, Washington, DC, USA.
14. File TM Jr, Low DE, Eckburg P et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter Phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51: 1395-405.
15. Corey GR, Wilcox M, Talbot GH et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51: 641-50.
16. Nannini EC, Stryjewski ME, Corey GR. Ceftaroline for complicated skin and skin-structure infections. Expert Opin Pharmacother 2010; 11: 1197-206.
17. Jacobs MR, Good CE, Windau AR et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2010; 54: 2716-9.
18. Morrissey I, Ge Y, Janes R. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents 2009; 33: 515-9.
19. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother 2010; 65: 713-6.
20. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other b-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2010; 54: 1670-7.
21. du Plessis M, Bingen E, Klugman KP. Analysis of penicillin-binding protein genes of clinical isolates of Streptococcus pneumoniae with reduced susceptibility to amoxicillin. Antimicrob Agents Chemother 2002; 46: 2349-57.
22. Nagai K, Davies TA, Jacobs MR et al. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother 2002; 46: 1273-80.
23. Zerfass I, Hakenbeck R, Denapaite D. An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: mutational analysis of Thr338. Antimicrob Agents Chemother 2009; 53: 1107-15.
24. McGee L, Biek D, Ge Y et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009; 53: 552-6.
25. Villegas-Estrada A, Lee M, Hesek D et al. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA b-lactam antibiotics. J Am Chem Soc 2008; 130: 9212-3.
26. File TM. Community-acquired pneumonia. Lancet 2003; 362: 1991-2001.
27. Critchley IA, Friedland HD, Eckburg P et al. Microbiological outcomes of 2 multicenter phase 3 clinical trials of ceftaroline in community-acquired bacterial pneumonia. In: Abstracts of the Annual American Thoracic Society Conference, New Orleans, LA, 2010. Poster #610.
28. Bradford PA, Petersen PJ, Tuckman M et al. In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia. Clin Microbiol Infect 2008; 14: 882-6.
29. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement M100-S18. CLSI, Wayne, PA, USA, 2008.